Disparities in Evaluation of Patients With Rectal Bleeding 40 Years and Older
Helen M. Shields(Beth Israel Deaconess Medical Center), Saul N. Weingart(Beth Israel Deaconess Medical Center), Stephen R. Pelletier(Harvard University), Jean M. Silk(Harvard University), Justin W. Li(National Patient Safety Foundation), Bonita L. Austin(Beth Israel Deaconess Medical Center), Elena M. Stoffel(University of Michigan), Susan E. Diguette(Harvard Vanguard Medical Associates), Thomas D. Sequist(Taos Orthopaedic Institute), Jean E. Furbish(Beth Israel Deaconess Medical Center), Daniel C. Chung(Massachusetts General Hospital), Justin Spencer(National Patient Safety Foundation), Ruth Lederman(Data Management (Italy))
Cited by 20
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932